Epidemiology and Comparative Effectiveness – How can epidemiology best contribute?
Two seminal reports, the first by the Institute of Medicine and the second by the Patient-Centered Outcomes Research Institute, focus on the priorities for comparative effectiveness research (CER). An important question is the role that observational, rather than interventional, studies can play in addressing the priorities raised in these two reports. It is likely that both financial and feasibility issues will limit the number of trials that can be conducted. Some questions that we’d like to address include:
· What areas of CER can be addressed by observational studies, particularly where trials may not be feasible?
· Can there be better analytical methods to control for indication bias in evaluating treatments?
· What can be contributed by existing cohorts, registries, medical data bases, and surveillance populations?
We welcome your comments and other questions that you would like to discuss.
Posted by the Epidemiology Branch, NHLBI